z K，Kolts RL，et al.Relationship Between Depression Severity Entry Criteria and Antidepressant Clinical Trial Outcomes[J].Biol Psychiatry，2006，47(7)：990
[13]Stein DJ，Baldwin DS，Dolberg OT，et al.Which factors predict placebo response in anxiety disorders and major depression An analysis of placebo-controlled studies of escitalopram[J].J Clin Psychiatry，2006，67(8)：1741
[14]Rothman KJ，Michels KB.The continuing unethical use of placebo controls[J].N Engl J Med 1994，331(5)：394
[15]Michels KB.The placebo problem remains[J].Arch Gen Psychiatry，2000，57(5)：321
[16]Charney DS，Nemeroff CB，Lewis L，et al.Consensus Development Panel. National Depressive and ManicDepressive Association consensus statement on the use of placebo in clinical trials of mood disorders[J].Arch Gen Psychiatry，2002，59(3)：262
[17]Khan A，Warner HA，Brown WA.Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials：an analysis of the Food and Drug Administration database[J]. Arch Gen Psychiatry，2000，57(5)：311
[18]Khan A，Schwartz K. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials：analysis of the FDA summary basis of approval reports[J].Ann Clin Psychiatry，2007，19(1)：31
[19]Leon AC.Can placebo controls reduce the number of nonresponders in clinical trials? A poweranalytic perspective[J].Clin Ther 2001，23(9)：596
[20]Thase ME，Friedman ES，Berman SR，et al.Is cognitive behavior therapy just a ‘nonspecific’ intervention for depression?A retrospective comparison of consecutive cohorts treated with cognitive behavior therapy or supportive counseling and pill placebo[J].J Affect Disord，2000，57(1)：63
上一页 [1] [2] [3] [4]
您现在的位置： 绿色健康网 >> 医学论文 >> 药学论文 >> 正文